Title:
ANTIBODY-DRUG CONJUGATE
Document Type and Number:
WIPO Patent Application WO/2014/057687
Kind Code:
A1
Abstract:
Provided is an antibody-drug conjugate which can be used as an anti-tumor agent that has an excellent anti-tumor effect and is highly safe, said conjugate being characterized by being produced by binding an anti-tumor compound represented by formula (1) to an antibody through a linker having a structure represented by the formula: -L1-L2-LP-NH-(CH2)n1-La-Lb-Lc- (wherein the antibody is bound at the terminal of L1, and the anti-tumor compound is bound at the terminal of Lc in which the binding site of the anti-tumor compound is a nitrogen atom in an amino group located at position-1).
Inventors:
MASUDA TAKESHI (JP)
NAITO HIROYUKI (JP)
NAKADA TAKASHI (JP)
YOSHIDA MASAO (JP)
ASHIDA SHINJI (JP)
MIYAZAKI HIDEKI (JP)
KASUYA YUJI (JP)
MORITA KOJI (JP)
ABE YUKI (JP)
OGITANI YUSUKE (JP)
NAITO HIROYUKI (JP)
NAKADA TAKASHI (JP)
YOSHIDA MASAO (JP)
ASHIDA SHINJI (JP)
MIYAZAKI HIDEKI (JP)
KASUYA YUJI (JP)
MORITA KOJI (JP)
ABE YUKI (JP)
OGITANI YUSUKE (JP)
Application Number:
PCT/JP2013/006069
Publication Date:
April 17, 2014
Filing Date:
October 10, 2013
Export Citation:
Assignee:
DAIICHI SANKYO CO LTD (JP)
International Classes:
C07K16/28; A61K39/395; A61P35/00; A61K31/4745; A61K31/48
Domestic Patent References:
| WO2002000734A1 | 2002-01-03 | |||
| WO1997046260A1 | 1997-12-11 | |||
| WO2000025825A1 | 2000-05-11 | |||
| WO2002043661A2 | 2002-06-06 | |||
| WO2006113909A2 | 2006-10-26 | |||
| WO1990007861A1 | 1990-07-26 | |||
| WO1992001047A1 | 1992-01-23 | |||
| WO1992020791A1 | 1992-11-26 | |||
| WO1993006213A1 | 1993-04-01 | |||
| WO1993011236A1 | 1993-06-10 | |||
| WO1993019172A1 | 1993-09-30 | |||
| WO1995001438A1 | 1995-01-12 | |||
| WO1995015388A1 | 1995-06-08 | |||
| WO1999054342A1 | 1999-10-28 | |||
| WO2000061739A1 | 2000-10-19 | |||
| WO2002031140A1 | 2002-04-18 | |||
| WO2003038043A2 | 2003-05-08 |
Foreign References:
| JP2009538629A | 2009-11-12 | |||
| JP2008521828A | 2008-06-26 | |||
| JP2005511627A | 2005-04-28 | |||
| JPH1192405A | 1999-04-06 | |||
| JPH1095802A | 1998-04-14 | |||
| JPH0559061A | 1993-03-09 | |||
| JPH08337584A | 1996-12-24 | |||
| US5773001A | 1998-06-30 | |||
| JPH0687746A | 1994-03-29 | |||
| JP2002060351A | 2002-02-26 | |||
| JP2005506035A | 2005-03-03 | |||
| JPH0848637A | 1996-02-20 | |||
| JP2008538292A | 2008-10-23 |
Other References:
DOSIO, F. ET AL.: "Antibody-targeted leucinostatin A.", JOURNAL OF CONTROLLED RELEASE, vol. 32, no. 1, November 1994 (1994-11-01), pages 37 - 44, XP025567275
DUCRY, L. ET AL.: "Antibody-Drug Conjugates: Linking cytotoxic payloads to monoclonal antibodies", BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
ALLEY, S. C. ET AL.: "Antibody-drug conjugates: targeted drug delivery for cancer", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 529 - 537
DAMLE N.K.: "Tumour-targeted chemotherapy with immunoconjugates of calicheamicin", EXPERT OPIN. BIOL. THER., vol. 4, 2004, pages 1445 - 1452
SENTER P. D. ET AL.: "The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma", NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 631 - 637
KUMAZAWA, E.; TOHGO, A.: "Antitumour activity of DX-8951f: a new camptothecin derivative", EXP. OPIN. INVEST. DRUGS, vol. 7, 1998, pages 625 - 632
MITSUI, I.; KUMAZAWA, E.; HIROTA, Y. ET AL.: "A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo", JPN J. CANCER RES., vol. 86, 1995, pages 776 - 786
TAKIGUCHI, S.; TOHGO, A. ET AL.: "Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice", JPN J. CANCER RES., vol. 88, 1997, pages 760 - 769
JOTO, N. ET AL.: "DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant", INT J CANCER, vol. 72, 1997, pages 680 - 686
KUMAZAWA, E. ET AL.: "Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice", CANCER CHEMOTHER. PHARMACOL., vol. 42, 1998, pages 210 - 220
DE JAGER, R. ET AL.: "DX-8951f: summary of phase I clinical trials", ANN N Y ACAD SCI, vol. 922, 2000, pages 260 - 273
MAEDA ET AL.: "Polymer Drugs in the Clinical Stage", 2003, article INOUE, K. ET AL.: "CM-dextran-polyalcohol-camptothecin conjugate, DE-310 with a novel carrier system and its preclinical data", pages: 145 - 153
KUMAZAWA, E. ET AL.: "DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine tumor models", CANCER SCI, vol. 95, 2004, pages 168 - 175
SOEPENBERG, 0. ET AL.: "Phase I and pharmacokinetic study of DE-310 in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 703 - 711
WENTE M. N. ET AL.: "DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors", INVESTIGATIONAL NEW DRUGS, vol. 23, 2005, pages 339 - 347
CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761
MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282
BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
KENNET, R.: "Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
KENNET, R.: "Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
SAIKI, R. K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 489
GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182
URLAUB, G.; CHASIN, L. A., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4126 - 4220
WEIR, D. M.: "Handbook of Experimental Immunology", vol. I-III, 1987, BLACKWELL SCIENTIFIC PUBLICATIONS
KABAT, E. A.; MAYER, M. M.: "Experimental Immunochemistry", 1964, CHARLES C THOMAS PUBLISHER SPRINGFIELD
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1977, pages 511
MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 550
WALSH, NATURE, vol. 266, 1977, pages 495
BARBARA, B. M.; STANLEY, M. S.: "Selected Methods in Cellular Immunology", 1980, W. H. FREEMAN AND COMPANY
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
NATURE, vol. 321, 1986, pages 522 - 525
ALTSCHUL, STEPHEN F.; THOMAS L. MADDEN; ALEJANDRO A. SCHAFFER; JINGHUI ZHANG; ZHENG ZHANG; WEBB MILLER; DAVID J. LIPMAN: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143
KUROIWA, Y. ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
KITAGAWA, Y., MATUDA, T. AND IIJIMA, S.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, article YOSHIDA, H. ET AL., pages: 69 - 73
TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727
WORMSTONE, I. M. ET AL., INVESTIGATIVE OPHTHALMOLOGY VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308
CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203
SIRIWARDENA, D. ET AL., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431
NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1105 - 1116
ANNU. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455
LORI BURTON, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 12, 2007, pages 265 - 273
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134
ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83
DANIEL R. MARSHAK ET AL.: "Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS
ED HARLOW AND DAVID LANE: "Antibodies: A Laboratory Manual.", 1988, COLD SPRING HARBOR LABORATORY
HERMANSON, G.T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, article "pp. 56-136, pp. 456-493", pages: 56 - 493
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
J. ORG. CHEM., vol. 51, 1986, pages 3196
See also references of EP 2907824A4
DUCRY, L. ET AL.: "Antibody-Drug Conjugates: Linking cytotoxic payloads to monoclonal antibodies", BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
ALLEY, S. C. ET AL.: "Antibody-drug conjugates: targeted drug delivery for cancer", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 529 - 537
DAMLE N.K.: "Tumour-targeted chemotherapy with immunoconjugates of calicheamicin", EXPERT OPIN. BIOL. THER., vol. 4, 2004, pages 1445 - 1452
SENTER P. D. ET AL.: "The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma", NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 631 - 637
KUMAZAWA, E.; TOHGO, A.: "Antitumour activity of DX-8951f: a new camptothecin derivative", EXP. OPIN. INVEST. DRUGS, vol. 7, 1998, pages 625 - 632
MITSUI, I.; KUMAZAWA, E.; HIROTA, Y. ET AL.: "A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo", JPN J. CANCER RES., vol. 86, 1995, pages 776 - 786
TAKIGUCHI, S.; TOHGO, A. ET AL.: "Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice", JPN J. CANCER RES., vol. 88, 1997, pages 760 - 769
JOTO, N. ET AL.: "DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant", INT J CANCER, vol. 72, 1997, pages 680 - 686
KUMAZAWA, E. ET AL.: "Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice", CANCER CHEMOTHER. PHARMACOL., vol. 42, 1998, pages 210 - 220
DE JAGER, R. ET AL.: "DX-8951f: summary of phase I clinical trials", ANN N Y ACAD SCI, vol. 922, 2000, pages 260 - 273
MAEDA ET AL.: "Polymer Drugs in the Clinical Stage", 2003, article INOUE, K. ET AL.: "CM-dextran-polyalcohol-camptothecin conjugate, DE-310 with a novel carrier system and its preclinical data", pages: 145 - 153
KUMAZAWA, E. ET AL.: "DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine tumor models", CANCER SCI, vol. 95, 2004, pages 168 - 175
SOEPENBERG, 0. ET AL.: "Phase I and pharmacokinetic study of DE-310 in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 703 - 711
WENTE M. N. ET AL.: "DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors", INVESTIGATIONAL NEW DRUGS, vol. 23, 2005, pages 339 - 347
CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761
MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282
BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
KENNET, R.: "Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
KENNET, R.: "Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
SAIKI, R. K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 489
GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182
URLAUB, G.; CHASIN, L. A., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4126 - 4220
WEIR, D. M.: "Handbook of Experimental Immunology", vol. I-III, 1987, BLACKWELL SCIENTIFIC PUBLICATIONS
KABAT, E. A.; MAYER, M. M.: "Experimental Immunochemistry", 1964, CHARLES C THOMAS PUBLISHER SPRINGFIELD
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1977, pages 511
MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 550
WALSH, NATURE, vol. 266, 1977, pages 495
BARBARA, B. M.; STANLEY, M. S.: "Selected Methods in Cellular Immunology", 1980, W. H. FREEMAN AND COMPANY
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
NATURE, vol. 321, 1986, pages 522 - 525
ALTSCHUL, STEPHEN F.; THOMAS L. MADDEN; ALEJANDRO A. SCHAFFER; JINGHUI ZHANG; ZHENG ZHANG; WEBB MILLER; DAVID J. LIPMAN: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143
KUROIWA, Y. ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
KITAGAWA, Y., MATUDA, T. AND IIJIMA, S.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, article YOSHIDA, H. ET AL., pages: 69 - 73
TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727
WORMSTONE, I. M. ET AL., INVESTIGATIVE OPHTHALMOLOGY VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308
CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203
SIRIWARDENA, D. ET AL., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431
NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1105 - 1116
ANNU. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455
LORI BURTON, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 12, 2007, pages 265 - 273
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134
ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83
DANIEL R. MARSHAK ET AL.: "Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS
ED HARLOW AND DAVID LANE: "Antibodies: A Laboratory Manual.", 1988, COLD SPRING HARBOR LABORATORY
HERMANSON, G.T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, article "pp. 56-136, pp. 456-493", pages: 56 - 493
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
J. ORG. CHEM., vol. 51, 1986, pages 3196
See also references of EP 2907824A4
Attorney, Agent or Firm:
OHNO, Seiji et al. (JP)
Seiji Ono (JP)
Seiji Ono (JP)
Download PDF: